NTRA Natera, Inc. Insider Trading

Daniel Rabinowitz (SEC & Chief Legal Officer) sells 16,800 shares for $4,574,430.59 via 12 transactions on 2026-07-01 under pre-arranged 10b5-1 plan.

Daniel Rabinowitz executed 12 separate sales totaling 16,800 shares for $4,574,430.59 on 2026-07-01 at prices ranging from $266.79 to $278.25, reducing his holdings from 189,094 to 172,294 shares. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-12-05, meaning it was scheduled rather than discretionary. The stock is trading at $283.80, approximately -1.5% from its 52-week high of $288.04, having appreciated +31.8% over the prior 30 days and +35.6% over the prior 90 days. Natera remains unprofitable on a full-year basis with net income of $-85,091,000.00, though the company showed strong revenue growth of +35.9% year-over-year and currently trades at a $40.6B market cap.

President of ClinicalDiagnostics sells 3,000 NTRA shares for $818.7K under 10b5-1 plan; holds 134.6K shares post-sale

Solomon Moshkevich sold 3,000 shares across three separate transactions on 2026-07-01 at prices ranging from $267.18 to $274.06, realizing $818,710.50, leaving him with 134,643 shares. This sale is part of a pre-arranged 10b5-1 trading plan adopted on 2024-11-26, meaning the transaction was scheduled rather than discretionary. His prior sales at Natera show consistent post-sale gains (30-day returns of +25.2%, +26.0%, +26.2%, +27.0%, and +11.2%), though these are outcome observations rather than timing indicators for this scheduled sale. The company is currently unprofitable with net income of $-85,091,000 in the latest quarter, but annual revenue growth stands at +35.9%, and the stock has risen +31.8% over the past 30 days and +35.6% over 90 days.

Daniel Rabinowitz sells 33,600 shares for $8,455,354.57 under pre-arranged 10b5-1 plan at NTRA

Daniel Rabinowitz, SEC and Chief Legal Officer, executed 4 separate sales totaling 33,600 shares for $8,455,354.57 on 2026-06-24 under a pre-arranged 10b5-1 trading plan adopted 2025-12-05. His holdings declined 15.1% to 189,094 shares post-transaction. The scheduled nature of the trades removes discretionary timing as an interpretive lens. Natera is a large-cap ($37.5B) high-growth company (revenue +35.9% annually) currently unprofitable ($-85.1M net income last fiscal year), with the stock up +29.0% over 30 days and +43.4% over 90 days. While his prior 5 sales at NTRA showed modest positive 30-day returns (+1.1% to +3.2%), this transaction's execution within a volatile, appreciating period is consistent with a prearranged schedule rather than a discretionary market-timing signal.

Director Herm Rosenman sold 16,530 shares of NTRA at $250.00 (total: $4,132,500.00) via pre-arranged 10b5-1 plan; retains 4,250 shares.

Herm Rosenman executed a substantial sale of 16,530 shares representing 79.5% of his pre-transaction holdings under a 10b5-1 trading plan adopted on 2025-12-11, leaving him with only 4,250 shares post-trade. The sale occurred at $250.00 while the stock currently trades at $261.91, within 3.5% of its 52-week high of $271.47; notably, this transaction is scheduled under a pre-arranged plan rather than discretionary, so timing characteristics do not apply to this filing. His prior NTRA transactions from December 2025 showed mixed near-term outcomes (30-day returns of 2.3%–3.4%) but consistent 90-day declines (−16.0% to −16.9%), whereas an earlier February 2024 sale achieved substantially stronger 90-day performance (+57.1%), suggesting inconsistent timing outcomes at this ticker. The company is growing revenue at 35.9% annually but remains unprofitable (latest quarter net loss $85.1M), a pattern that may inform the scale of this liquidation event.

Executive Chairman Rabinowitz sold 100,000 shares for $21.4M via pre-arranged 10b5-1 plan (2026-06-12 to 06-15)

Matthew Rabinowitz executed 21 separate sales totaling 100,000 shares (100.0K shares) for $21,447,307.52 across two trading days under a 10b5-1 trading plan adopted on 2026-03-13, meaning this was a scheduled transaction rather than a discretionary decision. The blended average price was $214.47, within the company's recent 52-week range of $131.81–$256.36. His post-transaction holdings of 2,277,843 shares (2.28M shares) represent a net reduction of 4.2% from pre-transaction levels. The company currently trades at $220.11 and reports $696.6M in quarterly revenue with annual growth of 35.9%, though it posted a net loss of $85.1M in the most recent quarter, indicating growth without current profitability; the scheduled nature of this sale under a pre-arranged plan limits inference about timing signals.

Natera director Gail Boxer Marcus sold 11,000 shares ($2.4M) in 4 transactions on 2026-06-05; holds 6,183 non-derivative shares post-sale.

Gail Boxer Marcus (Director) executed 4 separate sales totaling 11,000 shares for $2,389,328.01 at a blended average price of $217.21 on 2026-06-05, reducing non-derivative holdings by 64.0% to 6,183 shares. The insider retains derivative securities: 11,000 stock options (Table II), preserving significant upside exposure. Natera is growing revenue at +35.9% annually but remains unprofitable with a net loss of $85,091,000 over its latest fiscal year. At the transaction's blended price of $217.21, the stock was trading 13.1% below its 52-week high of $256.36, and has advanced 14.7% over the subsequent 30 days. Across the insider's prior NTRA sales (2024-11-19), neither proved well-timed at the 90-day mark (both showed positive returns after sale), indicating the stock rallied following those dispositions.

Then-CEO Steven Leonard Chapman sold 41,124 shares for $9,089,776.37 on 2026-06-04 via pre-arranged 10b5-1 plan.

Steven Leonard Chapman, who was CEO at the time, executed 14 separate sales totaling 41,124 shares for $9,089,776.37 on 2026-06-04, reducing his holdings from 149,867 shares to 108,743 shares. The transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on 2023-12-11, meaning the sales were scheduled rather than discretionary. This blended average price of $221.03 compares to the current price of $215.31, placing the transaction price above current levels. The company generated $696.6M in revenue during the latest quarter with negative annual net income of $-85.1M, suggesting profitability challenges despite 35.9% revenue growth year-over-year; Chapman's prior sales at NTRA have yielded subsequent 90-day returns ranging from +8.7% to +11.6%, indicating his earlier sales preceded periods of stock appreciation.

NTRA president sells 3,000 shares for $655,294.81 under 10b5-1 plan; stock now -17.4% from 52-week high

Solomon Moshkevich, president of ClinicalDiagnostics at Natera, executed 4 separate sales totaling 3,000 shares for $655,294.81 at prices ranging from $217.52 to $220.67 on 2026-06-01, reducing his holdings by 2.1% to 137,643 shares. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2024-11-26, making it scheduled rather than discretionary. The current stock price of $211.85 reflects a -17.4% decline from the 52-week high of $256.36, and while the company reported strong annual revenue growth of +35.9%, it remains unprofitable with a net income of $-85.1M in the latest full fiscal year. Investors should note the non-discretionary nature of this sale and the company's unprofitable status despite robust top-line growth.

Director Roelof Botha sold 78,000 shares at NTRA for $17.2M; 5 of 5 prior same-ticker sells were well-timed at 90-day mark.

Roelof Botha executed 6 separate sales totaling 78,000 shares for $17,184,092.05, reducing his holdings from 1,154,198 to 1,076,198 shares. His prior trade history at NTRA shows a consistent pattern: all 5 previous sales on 2025-11-24 were well-timed at the 90-day mark, with each recording negative 90-day returns ranging from -7.4% to -9.2%, indicating the stock declined after each sale. The company is unprofitable with net income of $-85,091,000.00 over its most recent full fiscal year, though revenue grew +35.9% year-over-year to $696,644,000.00. Current price of $211.85 is -17.4% from the 52-week high of $256.36, suggesting this director's historical execution pattern has aligned with subsequent price weakness.

NTRA President Moshkevich Solomon sold 3,000 shares for $610,065.16 via scheduled 10b5-1 plan

Moshkevich Solomon, President of Clinical Diagnostics at Natera Inc., executed 6 separate sales totaling 3,000 shares for $610,065.16 on 2026-05-01 at blended average price $203.36, reducing his holdings by 2.1% to 142,295 shares. The transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2024-11-26, meaning it is scheduled rather than discretionary. His prior trades at NTRA (5 sells) show subsequent 30-day and 90-day returns of +2.0% and +0.5% on average, while his broader cross-ticker track record across 20 prior sells shows average 90-day returns of -7.7%, suggesting mixed historical outcomes. With NTRA trading at $204.21 (down 19.7% from its 52-week high of $254.40 but up 5.8% over 30 days), and the company reporting negative net income of $-255,418,000.00 despite strong annual revenue growth of +272.3%, this scheduled disposition provides limited signal independent of the pre-arranged timing.